2025年9月，道尔生物完成向美国FDA递交DR10624注射液的临床试验申请，并于近日获得FDA批准。本次DR10624注射液美国临床试验申请获批，是该款产品研发进程中的又一重要进展，将进一步提升公司在内分泌治疗领域的核心竞争力。未来，公司将继续全力推进该产品的临床开发及注册工作，争取为广大患者提供更多的治疗选择!

Infrared vibrational spectroscopy at BESSY II can be used to create high-resolution maps of molecules inside live cells and cell organelles in native aqueous environment, according to a new study by a ...

2025年8月15日，北京生命科学研究和清华大学等研究者在国际顶级期刊《Cell》发表重要学术论文：Fibroblast bioelectric signaling drives hair growth（ 成纤维细胞的生物电信号驱动毛发生长 ...

Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.

A long-studied metabolic hormone, FGF21, also acts as a stress hormone—a discovery that helps explain how psychological stress causes metabolic dysregulation and drive physical disease, according to a ...

Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a ...

OCTOPOD-IV (NCT06618235) is a first-in-human, multi-centre trial to assess safety, tolerability and preliminary efficacy of THEO-260 in patients with high-grade serous ovarian or endometrioid cancer.

Researchers from Riga Technical University, the Technion-Israel Institute of Technology, and Tomas Bata University have published a comprehensive review in the journal Acta Pharmaceutica Sinica B ...

In one of the biggest deals of the waning year, Novo Nordisk A/S is buying Akero Therapeutics Inc. to bolster its metabolic ...

Seven years after the biotechnology firm launched, Akero Therapeutics is slated to be acquired by the Danish pharmaceutical ...

Denmark’s Novo Nordisk said on Thursday that it has agreed to buy Akero Therapeutics - a clinical-stage company developing ...

Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its ...